beta
Trial Radar AI
Clinical Trial NCT06544018 (ICARUS) for Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria, Muckle-Wells Syndrome, CINCA Syndrome is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View

Circadian Rhythm Deregulation in Patients With CAPS (ICARUS)

Not yet recruiting
Clinical Trial NCT06544018 (ICARUS) is an interventional study for Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria, Muckle-Wells Syndrome, CINCA Syndrome is not yet recruiting. Enrollment is planned to begin on 1 September 2025 until the trial accrues 30 participants. Led by Hospices Civils de Lyon, this trial is expected to complete by 1 November 2028. The latest data from ClinicalTrials.gov was last updated on 25 June 2025.
Brief Summary
Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within each cell. At the molecular level, the circadian clock is based on a complex system of cell-autonomous transcription loops. These exert positive and negative feedback on themselves, generating cyclic transcriptional activity.

  • In the main loop, the BMAL1 transcription factor links with CLOCK or NPAS2 ( (Neuronal PAS Domain Protein 2) to activate transcription of per1,2 and 3 and cryptochrome (cry1 and cry2), which in turn repress BMAL1/CLOCK1 transcriptional activity.. The BMAL1/CLOCK complex also activates transcription of numerous target genes (per and cry, Rev-erb, etc.)..
  • other secondary loops refine the function of the first.

Recent studies suggest that many aspects of innate immunity are controlled by circadian rhythm through inhibition of NLRP3 inflammasome activation. Nevertheless, the regulation of the NLRP3 inflammasome by the circadian clock has yet to be elucidated. Inflammasomes are molecular platforms that control caspase-1 activation and consequently the maturation of precursors of (interleukine) IL-1β, pro-IL-18, a pro-inflammatory cytokine. Since its discovery, its functions have been widely characterized as part of the innate immune response as a sensor of pathogens and danger signals (extracellular ATP (Adenosine triphosphate), atmospheric pollutants). NLRP3 (nucleotide-binding domain LRR (leucin-rich repeat ) and pyrin-containing receptor 3) has been described for its genetic association with dominant monogenic hereditary syndromes characterized by recurrent systemic inflammatory episodes in the absence of any infection or autoimmune disease, known as CAPS (cryopyrin-associated periodic syndrome) or cryopyrinopathies which is a continuum of diseases ranging from a moderate to the most severe form of the syndrome: familial cold urticaria syndrome, Muckle-Wells syndrome (MWS), and CINCA/NOMID syndrome.

Interestingly, patients with Muckle-Wells syndrome show a circadian pattern of symptoms, with a recurrent, predominantly vesperal fever peak lasting a few hours, and extreme fatigue on a daily basis. However, a molecular link between the circadian clock and CAPS pathology remains to be determined.

The aim of this protocol is to identify circadian rhythm dysregulation in patients with CAPS confirmed by genetic analysis of NLRP3, to demonstrate a link between circadian clock and CAPS syndrome, and to identify circadian clock regulatory pathways.

Official Title

Identification of Circadian Rhythm Deregulation in Patients With Cryopyrin-associated Periodic Syndrome (CAPS)

Conditions
Cryopyrin Associated Periodic SyndromeFamilial Cold UrticariaMuckle-wells SyndromeCINCA Syndrome
Other Study IDs
  • ICARUS
  • 69HCL23_0417
  • 2023-A01088-37 (Other Identifier) (ID-RCB)
NCT ID Number
Start Date (Actual)
2025-09-01
Last Update Posted
2025-06-25
Completion Date (Estimated)
2028-11-01
Enrollment (Estimated)
30
Study Type
Interventional
PHASE
N/A
Status
Not yet recruiting
Keywords
Circadian clock
cryopyrin-associated periodic syndrome
familial cold urticaria
muckle-wells syndrome
melatonin
Primary Purpose
Other
Design Allocation
Non-Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Active ComparatorPatients with cryopyrin-associated periodic syndrome (CAPS)
Confirmed by genetic analysis of NLRP3
Genetic Analysis of NLRP3
Blood test for genetic analysis of NLRP3
Circadian RHYTHM Measurement
Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm
Saliva Sampling
Saliva sampling for salivary melatonin determination
Questionnaire
Questionnaire to determine chronotype
AIDAI Score
Disease activity score using AIDAI score (only for patients in the CAPS group) AIDAI : AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX
Blood Sampling
1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18. 2. Molecular characterization of circadian clock signaling pathways
Placebo ComparatorControl group
Healthy participant (absence of CAPS, verified by NLRP3 gene analysis) living in the same household as a CAPS participant included in the protocol
Genetic Analysis of NLRP3
Blood test for genetic analysis of NLRP3
Circadian RHYTHM Measurement
Wear a Withings Pulse HR (heart rate) actigraphic watch 24 hours a day for 1 month to define circadian rhythm
Saliva Sampling
Saliva sampling for salivary melatonin determination
Questionnaire
Questionnaire to determine chronotype
Blood Sampling
1. Inflammatory cytokines measurement : IL1-beta (Interleukin-1) and IL-18. 2. Molecular characterization of circadian clock signaling pathways
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,
Concentration of the peak secretion of melatonin in both arms
6 months after inclusion
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,
Concentration of the peak secretion of melatonin in both arms
12 months after inclusion
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,
time of the peak secretion of melatonin in both arms
6 months after inclusion
Description of circadian rhythm deregulation in patients with cryopyrinopathy (CAPS) whose diagnosis was confirmed by genetic analysis of NLRP3,
time of the peak secretion of melatonin in both arms
12 months after inclusion
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.
Determination of circadian rhythms : amplitude in both arms
6 th month
Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.
Determination of circadian rhythms : period in both arms
6 th month
Difference in circadian clock biomarkers between patients and control participants for Circadian Rhythm Characteristics.
Determination of circadian rhythms : phase in both arms
6 th month
Chronotype determination
Number of patients in each chronotype for the 2 arms based on the specific questionnaire in both arm
6 th month
sleep duration
sleep duration in both arms
6 th month
number of steps
Daily activity in both arms
6 th month
Comparison of inflammatory state
basal levels of IL1β in patient monocytes in both arms
6 months after inclusion
Comparison of inflammatory state
basal levels of IL1β in patient monocytes in both arms
12 months after inclusion
Comparison of inflammatory state
basal levels of IL18 in patient monocytes in both arms
6 months after inclusion
Comparison of inflammatory state
basal levels of IL18 in patient monocytes in both arms
12 months after inclusion
Disease activity measurement
Number of patient with active disease ie AIDAI (AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX) score \>9 in CAPS patient arm
6 months after inclusion
Disease activity measurement
Number of patient with active disease ie AIDAI (AUTO-INFLAMMATORY DISEASE ACTIVITY INDEX) score \>9 in CAPS patient arm
12 months after inclusion
presence or absence of an abnormality in the NLRP3 signalling pathway in CAPS arm compared control arm
Biochemical characterization of the NLRP3 inflammasome protein regulatory pathway in both arms
6 months after inclusion
presence or absence of an abnormality in the NLRP3 signalling pathway in CAPS arm compared to control arm
Biochemical characterization of the NLRP3 inflammasome protein regulatory pathway in both arms
12 months after inclusion
presence or absence of ASC inflammasome protein regulatory pathway in CAPs arm compared to control arm
Biochemical characterization of the ASC inflammasome protein regulatory pathway in both arms
6 months after inclusion
presence or absence of ASC inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the ASC inflammasome protein regulatory pathway in both arms
12 months after inclusion
presence or absence of the CASPASE-1 inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the CASPASE-1 inflammasome protein regulatory pathway in both arms
6 months after inclusion
presence or absence of the CASPASE-1 inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the CASPASE-1 inflammasome protein regulatory pathway in both arms
12 months after inclusion
presence or absence of REV-ERBα inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the REV-ERBα inflammasome protein regulatory pathway in both arms
6 months after inclusion
presence or absence of REV-ERBα inflammasome protein regulatory pathway in CAPS arm compared to control arm
Biochemical characterization of the REV-ERBα inflammasome protein regulatory pathway in both arms
12 months after inclusion
Eligibility Criteria

Eligible Ages
Child, Adult, Older Adult
Minimum Age
6 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes

Patient with CAPS group :

  • Patients aged 6 and over
  • Participant with CAPS confirmed by NLRP3 genetic analysis
  • Weight greater than or equal to 25 Kg
  • Parents/guardians who have been informed of the study and have signed a consent form.
  • Patient affiliated to a social security scheme

Control group (healthy participant):

  • Participant aged 6 and over
  • Weight greater than or equal to 25 Kg
  • Participant living in the same household as a subject with CAPS genetically confirmed by NLRP3 analysis and included in the protocol
  • Participant with no CAPS (a priori) who consents to NLRP3 genetic analysis
  • Parents/guardians who have been informed of the study and have signed a consent form.
  • Participant who has been informed of the study and has agreed to take part
  • Participant affiliated to a social security scheme

Patient with CAPS group :

  • Patients with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin).
  • Patients with sleep apnea syndrome
  • Patients working regular night shifts or alternating day and night shifts
  • Pregnant or breast-feeding women
  • Parents with an infant under 6 months of age
  • Patient participating in another interventional drug study
  • Deprivation of civil rights (curators, guardianship, safeguard of justice)

Control group (healthy participant):

  • Participants with a chronic illness (ALD beneficiaries)
  • Participants with chronic sleep disorders (narcolepsy, hypersomnia) requiring medication (sleeping pills, melatonin)
  • Participants working regular night shifts or alternating day and night shifts
  • Pregnant or breast-feeding women
  • Parents with an infant under 6 months of age
  • Participant participating in another interventional drug study
  • Deprivation of civil rights (curators, guardianship, safeguard of justice)
Hospices Civils de Lyon logoHospices Civils de Lyon
Study Central Contact
Contact: Alexandre Alexandre, PR, 04 27 85 61 26, [email protected]
Contact: Samira Plassart, 04 27 85 54 42, [email protected]
6 Study Locations in 1 Countries
Hôpital Femme-Mère-Enfant (HCL), Bron, 69677, France
Alexandre Belot, MD;PhD, Contact, 04 27 85 61 26, [email protected]
Alexandre Belot, MD;PhD, Principal Investigator
Hôpital Claude Huriez (CHU de Lille), Lille, 59037, France
Éric HACHULLA, MD;PhD, Contact, [email protected]
Éric HACHULLA, MD;PhD, Principal Investigator
Hôpital de la Croix-Rousse (HCL), Lyon, 69004, France
Yvan Jamilloux, MD;PhD, Contact, [email protected]
Yvan Jamilloux, MD;PhD, Principal Investigator
Hôpital Edouard Herriot (HCL), Lyon, 69437, France
Thomas Barba, MD, Contact, [email protected]
Thomas Barba, MD, Principal Investigator
Hôpital Tenon (AP-HP), Paris, 75020, France
Sophie Georgin-Lavialle, MD;PhD, Contact, 01 56 01 60 77, [email protected]
Sophie Georgin-Lavialle, MD;PhD, Principal Investigator
Hôpital Kremlin-Bicêtre (AP-HP), Paris, 94270, France
Isabelle Koné-Paut, MD;PhD, Contact, 01 45 21 32 46, [email protected]
Isabelle Koné-Paut, MD;PhD, Principal Investigator